UA102849C2 - Способ продолжительного лечения эндометриоза и фибромы матки - Google Patents
Способ продолжительного лечения эндометриоза и фибромы маткиInfo
- Publication number
- UA102849C2 UA102849C2 UAA201014039A UAA201014039A UA102849C2 UA 102849 C2 UA102849 C2 UA 102849C2 UA A201014039 A UAA201014039 A UA A201014039A UA A201014039 A UAA201014039 A UA A201014039A UA 102849 C2 UA102849 C2 UA 102849C2
- Authority
- UA
- Ukraine
- Prior art keywords
- endometriosis
- treatment
- estrogen
- uterine fibroids
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 201000009273 Endometriosis Diseases 0.000 title abstract 3
- 206010046798 Uterine leiomyoma Diseases 0.000 title 1
- 201000010260 leiomyoma Diseases 0.000 title 1
- 229940011871 estrogen Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940123788 Progesterone receptor antagonist Drugs 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 239000002834 estrogen receptor modulator Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4847208P | 2008-04-28 | 2008-04-28 | |
| PCT/US2009/041826 WO2009134718A1 (en) | 2008-04-28 | 2009-04-27 | Pregesteron antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA102849C2 true UA102849C2 (ru) | 2013-08-27 |
Family
ID=40751037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201014039A UA102849C2 (ru) | 2008-04-28 | 2009-04-27 | Способ продолжительного лечения эндометриоза и фибромы матки |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8426394B2 (enExample) |
| EP (1) | EP2293797B1 (enExample) |
| JP (1) | JP5791499B2 (enExample) |
| KR (2) | KR20130059442A (enExample) |
| CN (2) | CN105616427A (enExample) |
| AR (1) | AR071516A1 (enExample) |
| AU (1) | AU2009241355B2 (enExample) |
| BR (1) | BRPI0911563A2 (enExample) |
| CA (1) | CA2722753C (enExample) |
| CL (1) | CL2009001010A1 (enExample) |
| DK (1) | DK2293797T3 (enExample) |
| EA (3) | EA201071249A1 (enExample) |
| ES (1) | ES2561810T3 (enExample) |
| IL (1) | IL208844A0 (enExample) |
| ME (1) | ME01123B (enExample) |
| MX (1) | MX2010011272A (enExample) |
| MY (1) | MY161059A (enExample) |
| NI (1) | NI201000183A (enExample) |
| NZ (1) | NZ589533A (enExample) |
| SG (1) | SG10201408483QA (enExample) |
| TW (1) | TWI477276B (enExample) |
| UA (1) | UA102849C2 (enExample) |
| WO (1) | WO2009134718A1 (enExample) |
| ZA (1) | ZA201007529B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI477276B (zh) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| TWI539953B (zh) * | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
| HUP0900487A2 (hu) * | 2009-08-05 | 2011-03-28 | Richter Gedeon Nyrt | 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására |
| UA113283C2 (xx) * | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| EP2471537A1 (en) * | 2010-12-30 | 2012-07-04 | PregLem S.A. | Treatment of pain associated with dislocation of basal endometrium |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| EP2854763B1 (en) * | 2012-05-31 | 2018-09-26 | Repros Therapeutics Inc. | Formulations for vaginal delivery of antiprogestins |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| JP6343619B2 (ja) * | 2012-11-02 | 2018-06-13 | レプロス セラピューティクス インコーポレイティド | プロゲステロン依存性病態を処置する方法およびその組成物 |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| HU230381B1 (hu) * | 2014-02-17 | 2016-03-29 | Richter Gedeon Nyrt | Ipari eljárás szteroid intermedier előállítására |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| EP3174542A4 (en) | 2014-07-29 | 2018-01-03 | TherapeuticsMD, Inc. | Transdermal cream |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2377418A1 (fr) * | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
| FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| ATE151286T1 (de) | 1983-11-14 | 1997-04-15 | Columbia Lab Inc | Bioadhäsive mittel |
| FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5439913A (en) * | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| US5468741A (en) | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
| PL178174B1 (pl) * | 1993-11-16 | 2000-03-31 | Garfield Robert E | Kompozycje farmaceutyczne do hamowania kurczliwości macicy lub stymulowania kurczliwości macicy |
| DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| SK282570B6 (sk) * | 1995-02-02 | 2002-10-08 | Schering Aktiengesellschaft | Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania |
| DE69702450T2 (de) * | 1996-05-01 | 2001-03-08 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | 21-substituierte progesteron derivate als antigestagene |
| US6900193B1 (en) * | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| AU2805397A (en) | 1996-08-30 | 1998-03-19 | Population Council, Center For Biomedical Research, The | Vaginal application mifepristone |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| US6172052B1 (en) | 1998-12-04 | 2001-01-09 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| EP1008443A1 (de) | 1998-12-08 | 2000-06-14 | Alusuisse Technology & Management AG | Sterilisierbarer Folienverbund für Verpackungszwecke |
| US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
| DK1265911T3 (da) * | 2000-03-17 | 2008-09-29 | Us Gov Health & Human Serv | 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler |
| IN191020B (enExample) * | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
| CA2405500C (en) | 2000-04-03 | 2006-08-22 | Astenjohnson, Inc. | Pre-crimped tie components |
| US7378406B2 (en) * | 2000-10-18 | 2008-05-27 | Schering Ag | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| DE60228583D1 (de) | 2001-07-09 | 2008-10-09 | Repros Therapeutics Inc | Verfahren und materialien für die behandlung des testosteron-mangels bei männern |
| US7833545B2 (en) | 2003-04-29 | 2010-11-16 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
| EP1593376A1 (en) | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
| AU2005265357B2 (en) * | 2004-07-09 | 2011-04-07 | Laboratoire Hra Pharma | Sustained release compositions containing progesterone receptor modulators |
| GT200500185A (es) * | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| DE102005028970A1 (de) * | 2005-06-22 | 2006-12-28 | Siemens Ag | Piezoakter mit gesteigertem Hubvermögen |
| DE102005030294A1 (de) | 2005-06-24 | 2007-01-04 | Schering Ag | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| US8173626B2 (en) * | 2006-03-08 | 2012-05-08 | Danco Laboratories Llc | Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders |
| ES2643318T3 (es) | 2006-10-24 | 2017-11-22 | Repros Therapeutics Inc. | Composiciones y métodos para suprimir la proliferación endometrial |
| EP2125858A2 (en) * | 2007-01-17 | 2009-12-02 | Repros Therapeutics Inc. | Pharmaceutically acceptable salts of 11-(4-aminophenyl)-19-norpregna-4,9(10)-diene-3,20-dione derivatives |
| CA2682752C (en) | 2007-04-05 | 2015-07-07 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
| HRP20160689T1 (hr) * | 2007-04-20 | 2016-07-15 | Preglem S.A. | Selektivni modulatori progesterona za tretman uterinog krvarenja |
| TWI477276B (zh) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| JP5992330B2 (ja) | 2009-09-29 | 2016-09-14 | メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ | 物質を投与するための子宮内電子カプセル |
-
2009
- 2009-04-09 TW TW098111780A patent/TWI477276B/zh not_active IP Right Cessation
- 2009-04-27 EA EA201071249A patent/EA201071249A1/ru unknown
- 2009-04-27 US US12/990,203 patent/US8426394B2/en not_active Expired - Fee Related
- 2009-04-27 MY MYPI2010004777A patent/MY161059A/en unknown
- 2009-04-27 CN CN201610029200.9A patent/CN105616427A/zh active Pending
- 2009-04-27 AU AU2009241355A patent/AU2009241355B2/en not_active Ceased
- 2009-04-27 BR BRPI0911563A patent/BRPI0911563A2/pt not_active Application Discontinuation
- 2009-04-27 MX MX2010011272A patent/MX2010011272A/es active IP Right Grant
- 2009-04-27 ES ES09739520.6T patent/ES2561810T3/es active Active
- 2009-04-27 UA UAA201014039A patent/UA102849C2/ru unknown
- 2009-04-27 SG SG10201408483QA patent/SG10201408483QA/en unknown
- 2009-04-27 KR KR1020137009925A patent/KR20130059442A/ko not_active Ceased
- 2009-04-27 WO PCT/US2009/041826 patent/WO2009134718A1/en not_active Ceased
- 2009-04-27 CN CN2009801149788A patent/CN102014923A/zh active Pending
- 2009-04-27 KR KR20107026587A patent/KR20110014162A/ko not_active Ceased
- 2009-04-27 CA CA2722753A patent/CA2722753C/en not_active Expired - Fee Related
- 2009-04-27 EA EA201401347A patent/EA032646B1/ru not_active IP Right Cessation
- 2009-04-27 DK DK09739520.6T patent/DK2293797T3/en active
- 2009-04-27 JP JP2011506497A patent/JP5791499B2/ja not_active Expired - Fee Related
- 2009-04-27 NZ NZ589533A patent/NZ589533A/en not_active IP Right Cessation
- 2009-04-27 ME MEP-2010-182A patent/ME01123B/me unknown
- 2009-04-27 EA EA201990835A patent/EA201990835A3/ru unknown
- 2009-04-27 EP EP09739520.6A patent/EP2293797B1/en not_active Not-in-force
- 2009-04-28 AR ARP090101513 patent/AR071516A1/es unknown
- 2009-04-28 CL CL2009001010A patent/CL2009001010A1/es unknown
-
2010
- 2010-10-20 IL IL208844A patent/IL208844A0/en unknown
- 2010-10-21 ZA ZA2010/07529A patent/ZA201007529B/en unknown
- 2010-10-27 NI NI201000183A patent/NI201000183A/es unknown
-
2013
- 2013-04-02 US US13/855,559 patent/US8735381B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY161059A (en) | Progesterone antagonists such as cdb-4214 in the treatment of embodimetriosis, uterine fibroids, dysmenorrhea, breast cancer etc | |
| MY150763A (en) | Compositions and methods for suppressing endometrial proliferation | |
| MY161549A (en) | Progesterone antagonists such as cdb-4124 in the treatment of breast cancer | |
| EA200900203A1 (ru) | Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение | |
| MX2014004202A (es) | Uso post-agudo y profiláctico de progesterona para mejores resultados asociados con concusión. | |
| MX2009009581A (es) | Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta. | |
| GB201104241D0 (en) | Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same | |
| WO2007133816A3 (en) | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists | |
| WO2011031524A3 (en) | Methods and compositions for delivering interleukin-1 receptor antagonist | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2012006320A (es) | Composiciones de amantadina y metodos para su uso. | |
| PH12013500411A1 (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| EP2582371A4 (en) | METHOD FOR TREATING OR PREVENTING ESTROGEN-MEDIATED DISEASES | |
| WO2010097788A3 (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
| EA201171215A1 (ru) | Стоматологическое анестезирующее средство для интраназального введения, содержащее тетракаин и вазоконстриктор | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| EA201590522A1 (ru) | Способы введения рифаксимина для снижения веса и лечения ожирения | |
| WO2009134725A3 (en) | Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc | |
| MX2009009332A (es) | Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis. | |
| PT2435443E (pt) | Inibidores à base de aminopirazole triazolotiadiazole da proteína quinase c met | |
| MX367580B (es) | El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer. | |
| TN2017000482A1 (en) | Selective progesterone receptor modulator (sprm) regimen. | |
| UA98124C2 (ru) | Применение антагониста прогестерона для лечения эндометриоза | |
| TN2015000454A1 (en) | Progesterone receptor antagonist dosage form | |
| UA90568U (uk) | Спосіб комплексної терапії овець та кіз з гіполютеолізом |